DJIA 18,232.02 -53.72 -0.29%
NASDAQ 5,089.36 -1.43 -0.03%
S&P 500 2,126.06 -4.76 -0.22%
market minute promo

Vertex Pharmaceuticals (NASDAQ: VRTX)

125.08 0.03 (0.02%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

VRTX $125.08 0.02%
Company Photos
(Click to zoom)
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $124.91
Previous Close $125.05
Daily Range $124.33 - $125.96
52-Week Range $63.68 - $137.50
Market Cap $30.5B
P/E Ratio -42.10
Dividend (Yield) $0.00 (0.0%)
Volume 1,174,654
Average Daily Volume 1,629,445
Current FY EPS -$1.92




Drug Makers

Vertex Pharmaceuticals (VRTX) Description

The Company is in the business of discovering, developing and commercializing small molecule drugs for the treatment of serious diseases. Website:

News & Commentary

3 Types of Risks Facing Biotech Stocks

Biotech stocks have been dramatically outperforming the broader market, but that doesn't mean they're free of risk. Here are three types of risks all biotech stocks face.

Lee Ainslie Adds 90 New Stocks to His Portfolio Within the First Quarter

Could This Tiny Biotech Be on Gilead Sciences’ M&A Radar?

Gilead Sciences is on the the prowl for potential buyout targets. This little-known immuno-therapy company looks like a perfect match for the biotech in many ways. Here's why.

S&P 500 Movers: GMCR, NFLX

Vertex: The FDA Advisory Committee Recommended Approval For Orkambi

Nasdaq 100 Movers: VRTX, VIP

Vertex Pharmaceuticals' Orkambi Wins FDA Panel Backing - Analyst Blog

Analysts Confident That Vertex Pharmaceuticals' CF Drug Will Receive FDA Approval

Biotech Stock Roundup: Alexion to Buy Synageva, FDA Panel Backs Vertex's Orkambi - Analyst Blog

Vertex Pharmaceuticals (VRTX) Stock Climbs Following FDA Advisory Panel Aprroval

See More VRTX News...

VRTX's Top Competitors

VRTX $125.08 (0.02%)
Current stock: VRTX
AMGN $163.59 (-0.15%)
Current stock: AMGN
GILD $111.71 (0.44%)
Current stock: GILD
BIIB $398.68 (-0.62%)
Current stock: BIIB